Biobeat Releases Interim Data on Heart Patch
The single-use device tracks heart rate and blood pressure for 24 hours in a 600-patient trial.
Updated on Oct. 28, 2026 in Heart Disease
Live Poll
Would you trust a wearable chest patch over a traditional blood pressure cuff for medical diagnosis?
Biobeat has released interim data from a 600-patient clinical trial for its FDA-cleared, single-use chest patch. The device continuously monitors blood pressure and heart rate over a 24-hour period for use by patients and their medical providers.
Why it matters
This technology provides an alternative to traditional arm-cuff monitors for tracking vital signs throughout the day. The data arrives as the 2025 AHA/ACC hypertension guideline explicitly advises against using cuffless devices for clinical diagnosis of high blood pressure.
Biobeat released interim results from a 600-patient trial evaluating the performance of its chest-worn patch. The study focuses on the device's ability to monitor vital signs over a 24-hour duration, though comparative accuracy data remains under investigation.
The players
Biobeat
A medical technology company focused on wearable vital sign monitoring devices including chest patches.
American Heart Association (AHA)
A professional organization that develops evidence-based guidelines for cardiovascular health and hypertension management.
American College of Cardiology (ACC)
A professional society that partners with the AHA to define standards for cardiac care and diagnosis.
The details
The device functions as a single-use, chest-worn patch designed to continuously track heart rate and blood pressure. By collecting data over a full 24-hour cycle, the patch aims to capture a more complete picture of cardiovascular metrics than periodic spot checks. The system is designed to interface with clinical monitoring protocols.
Timeline
2025: The AHA/ACC published new hypertension guidelines regarding the use of cuffless monitoring technology.
Health Landscape
This development highlights the ongoing tension between rapidly evolving wearable sensor technology and established clinical diagnostic standards. The findings arrive as the 2025 AHA/ACC hypertension guideline explicitly advises against the use of cuffless monitoring devices for formal diagnosis.
If you are considering using wearable technology to track your blood pressure, be aware that clinical guidelines currently prioritize traditional arm-cuff monitors for diagnosis. Discuss any discrepancies between home-monitored readings and your primary care physician's results during your next visit.
The takeaway
While wearable patches offer convenient, continuous data collection, they are not currently a replacement for traditional diagnostic tools in a clinical setting. Always confirm the validity of your home monitoring methods with your doctor before making changes to your cardiovascular care plan.
Further reading
For more information on the evolving standards for cardiovascular diagnostics, visit the Heart Disease section.
Source note: This article includes information reported by Insights.
Live Poll
Would you trust a wearable chest patch over a traditional blood pressure cuff for medical diagnosis?
